MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Calithera Biosciences Company Profile (NASDAQ:CALA)

Consensus Ratings for Calithera Biosciences (NASDAQ:CALA) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.00 (203.03% upside)

Analysts' Ratings History for Calithera Biosciences (NASDAQ:CALA)
Show:
DateFirmActionRatingPrice TargetActions
6/8/2016JMP SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Wells FargoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$20.00 -> $12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/10/2015Leerink SwannLower Price TargetOutperform$19.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/24/2015Citigroup Inc.Initiated CoverageBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Calithera Biosciences (NASDAQ:CALA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q1($0.47)($0.52)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415($0.56)($0.44)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q3($0.52)($0.49)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.45)($0.44)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/17/2014($0.28)($16.85)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Calithera Biosciences (NASDAQ:CALA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.52)($0.52)($0.52)
Q3 20161($0.56)($0.56)($0.56)
Q4 20161($0.60)($0.60)($0.60)
(Data provided by Zacks Investment Research)
Dividend History for Calithera Biosciences (NASDAQ:CALA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Calithera Biosciences (NASDAQ:CALA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/16/2015Curtis HechtVPSell970$6.58$6,382.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2015Adage Capital Partners Gp LlcMajor ShareholderBuy106,968$6.03$645,017.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2015Adage Capital Partners Gp LlcMajor ShareholderBuy90,300$5.93$535,479.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Adage Capital Partners Gp LlcMajor ShareholderBuy172,126$5.27$907,104.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2014Adage Capital Partners Gp LlcMajor ShareholderBuy181,700$6.96$1,264,632.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2014Jean GeorgeDirectorBuy300,000$10.00$3,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2014Morgenthaler Venture PartnersMajor ShareholderBuy350,000$10.00$3,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Adage Capital Partners Gp LlcMajor ShareholderBuy800,000$10.00$8,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Calithera Biosciences (NASDAQ:CALA)
DateHeadline
06/23/16 03:20 PMTrending Tickers: Calithera Biosciences, Inc. (NASDAQ:CALA), Brightcove Inc. (NASDAQ:BCOV), Pacira ... - KC Register
06/23/16 11:04 AMStrong Buy Calls Count For Calithera Biosciences, Inc. (NASDAQ:CALA) At 2 - Investor Newswire
06/16/16 03:07 PMCALITHERA BIOSCIENCES, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/10/16 11:33 AMCalithera Biosciences, Inc. (NASDAQ:CALA) decreased -7.34%: Target Corp. (NYSE:TGT), YOU On Demand Holdings ... - KC Register
06/08/16 05:04 PMCalithera Biosciences, Inc. :CALA-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -
06/06/16 02:54 PMCalithera Biosciences (CALA) Announces Presentation of Positive CB-839 Data in TNBC at ASCO - StreetInsider.com
06/06/16 08:26 AMCalithera Reports CB-839 Phase I Solid Tumor Combo Data at ASCO
06/06/16 06:31 AM7:31 am Calithera Biosciences ASCO data demonstrated the clinical activity, tolerability and unique mechanism of action of CB-839 in patients with renal cell carcinoma and triple negative breast cancer (:TNBC) -
06/06/16 06:30 AMCalithera Biosciences Reports CB-839 Phase I Solid Tumor Combination Data at the American Society of Clinical Oncology Annual Meeting - [GlobeNewswire] - Future development to focus on renal cell carcinoma and triple negative breast cancer Calithera to host investor webcast on June 6, 2015 at 6:30 p.m. CT. SOUTH SAN FRANCISCO, Calif., June 06, 2016-- Calithera ...
06/01/16 09:11 PMCalithera Biosciences, Inc. (NASDAQ:CALA) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News - Calithera Biosciences, Inc. (NASDAQ:CALA) Do Brokers Advise Buy, Sell Or Hold?Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Calithera Biosciences, Inc. (NASDAQ:CALA). The latest reports which are currently in issue on Wednesday 1st of June state 0 analysts have a rating of “strong buy”, 0 ...and more »
05/28/16 10:16 AMCalithera Biosciences, Inc. (NASDAQ:CALA) Closes At $5.07 - Investor Newswire - Calithera Biosciences, Inc. (NASDAQ:CALA) Closes At $5.07Investor NewswireYesterday, the stock of Calithera Biosciences, Inc. (NASDAQ:CALA) closed at $5.07 after opening at $5.06 and registering high of $5.12 and low of $4.95. The last price is $-6.19 off 1-year high of $11.17 and $0.91 away from low of $4.07 during same period.
05/26/16 10:25 AMCalithera Biosciences, Inc. (NASDAQ:CALA) Quarterly EPS From Continuing Operations Stands At $-0.5211 - RealistInvestor.com - Calithera Biosciences, Inc. (NASDAQ:CALA) Quarterly EPS From Continuing Operations Stands At $-0.5211RealistInvestor.comFor the year ended 2016-03-31 Calithera Biosciences, Inc. (NASDAQ:CALA) basic consolidated EPS reported was $-1.809. For the quarter ended 2016-03-31, it came at $-1.809. EPS is a part of a firm's earnings that is owed to each outstanding stock.
05/11/16 09:09 AMEdited Transcript of CALA earnings conference call or presentation 10-May-16 8:30pm GMT -
05/10/16 05:52 PMCalithera reports 1Q loss -
05/10/16 03:38 PMCalithera Biosciences Reports First Quarter 2016 Financial Results and Recent Highlights - [at noodls] - - CB-839 Phase 1b Clinical Data to be Presented at ASCO 2016 - Key clinical leadership expansion - Calithera to Host Conference Call Today at 4:30pm Eastern Time SOUTH SAN FRANCISCO, Calif., May 10, 2016 ...
05/10/16 03:30 PMCalithera Biosciences Inc Earnings Call scheduled for 4:30 pm ET today -
05/10/16 06:07 AMQ1 2016 Calithera Biosciences Inc Earnings Release - Time Not Supplied -
05/03/16 08:10 AMCalithera Biosciences to Report First Quarter 2016 Financial Results on Tuesday, May 10, 2016 - [at noodls] - SOUTH SAN FRANCISCO, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule ...
04/21/16 08:27 AMCalithera Biosciences Announces Clinical Data Presentations at ASCO 2016 - [at noodls] - SOUTH SAN FRANCISCO, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA) a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule ...
04/18/16 08:12 AMCalithera Biosciences Announces Four Preclinical Presentations at the American Association for Cancer Research Annual Meeting 2016 - [at noodls] - SOUTH SAN FRANCISCO, Calif., April 18, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, ...
03/08/16 08:00 AMCalithera Biosciences to Report Fourth Quarter and Year-End 2015 Financial Results on Tuesday, March 15, 2016 - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 08, 2016-- Calithera Biosciences, Inc., a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor ...
03/02/16 03:06 PMCALITHERA BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement -
03/01/16 08:00 AMCalithera Biosciences to Present at Cowen and Company 36th Annual Health Care Conference - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 01, 2016-- Calithera Biosciences, Inc., a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor ...
02/26/16 10:58 AMLatest Analysts Reports On Calithera Biosciences, Inc. (NASDAQ:CALA) - Risers & Fallers - Latest Analysts Reports On Calithera Biosciences, Inc. (NASDAQ:CALA)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Calithera Biosciences, Inc. (NASDAQ:CALA). The latest broker reports which have been released state 2 analysts have a rating of “buy”, 1 analysts “outperform”, 0 analysts ...
02/21/16 01:59 PMCalithera Biosciences Incorporated (NASDAQ:CALA) Short Interest Decreased By 17.15% - Business Standard Tribune - Calithera Biosciences Incorporated (NASDAQ:CALA) Short Interest Decreased By 17.15%Business Standard TribuneThe short interest to Calithera Biosciences Incorporated's float is 31.31%. The stock decreased 2.61% or $0.15 during the last trading session, hitting $5.59. About 76,988 shares traded hands. Calithera Biosciences Inc (NASDAQ:CALA) has declined 16.57% ...
02/21/16 01:59 PMCan Calithera Biosciences, Inc. (NASDAQ:CALA) Surprise Analysts this Quarter? - Investor Newswire - Can Calithera Biosciences, Inc. (NASDAQ:CALA) Surprise Analysts this Quarter?Investor NewswireIn the most recent quarter, Calithera Biosciences, Inc. (NASDAQ:CALA) reported an earnings surprise of 9.26% when the firm last announced their results for the period ending on 2015-09-30. The actual earnings per share number of $-0.49 was $0.05 away ...and more »
02/21/16 01:59 PMAnalysts Bullish on Calithera Biosciences Inc (CALA) EPS - RiversideGazette.com - Analysts Bullish on Calithera Biosciences Inc (CALA) EPSRiversideGazette.comWall Street await Calithera Biosciences Inc (NASDAQ:CALA) to release earnings on February, 22. After releasing $-0.49 EPS for the previous quarter, Calithera Biosciences Inc's analysts now forecasts 12.24% negative EPS growth. The stock decreased ...
02/14/16 12:50 PMCalithera Biosciences Incorporated (NASDAQ:CALA) Shorts Decreased by 17.15% After Short Covering - fdanewsalert.com - Calithera Biosciences Incorporated (NASDAQ:CALA) Shorts Decreased by 17.15% After Short Coveringfdanewsalert.comThe short interest to Calithera Biosciences Incorporated's float is 31.31%. The stock increased 6.05% or $0.29 on February 12, hitting $5.08. About 87,623 shares traded hands. Calithera Biosciences Inc (NASDAQ:CALA) has declined 24.96% since July 10, ...Are Analysts Bearish Calithera Biosciences Inc (NASDAQ:CALA) After Last Week?Sonoran Weekly Reviewall 4 news articles »
02/09/16 01:24 PMEarnings Per Share for Calithera Biosciences Inc (CALA) to Decline - OctaFinance.com - Earnings Per Share for Calithera Biosciences Inc (CALA) to DeclineOctaFinance.comAnalysts await Calithera Biosciences Inc (NASDAQ:CALA) to reports earnings on February, 8. After $-0.49 actual EPS reported by Calithera Biosciences Inc for the previous quarter, Wall Street now forecasts 12.24 % negative EPS growth. The stock ...Calithera Biosciences Incorporated (NASDAQ:CALA) Shorted Shares Increased By 8.41%fdanewsalert.comZacks: Calithera Biosciences Inc (NASDAQ:CALA) Given $13.00 Consensus Target Price by AnalystsDaily Politicalall 3 news articles »
02/08/16 01:23 PMCalithera Biosciences Incorporated (NASDAQ:CALA) Shorted Shares Increased By 8.41% - fdanewsalert.com - Calithera Biosciences Incorporated (NASDAQ:CALA) Shorted Shares Increased By 8.41%fdanewsalert.comThe short interest to Calithera Biosciences Incorporated's float is 37.79%. The stock decreased 1.45% or $0.07 on February 5, hitting $4.76. Calithera Biosciences Inc (NASDAQ:CALA) has declined 31.51% since July 2, 2015 and is downtrending.Earnings Per Share for Calithera Biosciences Inc (CALA) to DeclineOctaFinance.comZacks: Calithera Biosciences Inc (NASDAQ:CALA) Given $13.00 Consensus Target Price by AnalystsDaily Politicalall 3 news articles »
02/04/16 12:56 PMPrice Target Update On Calithera Biosciences, Inc. (NASDAQ:CALA) - Risers & Fallers - Price Target Update On Calithera Biosciences, Inc. (NASDAQ:CALA)Risers & FallersA number of investment brokers have recently updated their price targets on shares of Calithera Biosciences, Inc. (NASDAQ:CALA). According to the latest broker reports 2 analysts have a rating of “buy”, 1 analysts “outperform”, 0 analysts “hold”, 0 ...
02/03/16 12:30 PMCalithera Biosciences, Inc. (NASDAQ:CALA): Quarterly Earnings Update - Investor Newswire - Calithera Biosciences, Inc. (NASDAQ:CALA): Quarterly Earnings UpdateInvestor NewswireAs per the research firms that were included in Zacks Research survey, Calithera Biosciences, Inc. (NASDAQ:CALA) is projected an EPS of $-0.65 for last quarter. The firm can release the earnings report on or around 2016-02-08. Since the ratings ...
02/02/16 08:00 AMCalithera Biosciences to Present at the BIO CEO & Investor and Leerink Global Healthcare Conferences in February - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Feb. 02, 2016-- Calithera Biosciences, Inc., a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor ...
01/31/16 06:55 PMCompany Shares of Calithera Biosciences, Inc. (NASDAQ:CALA) Drops by -11.5% - Bull Report - Company Shares of Calithera Biosciences, Inc. (NASDAQ:CALA) Drops by -11.5%Bull ReportCalithera Biosciences, Inc. (NASDAQ:CALA) has lost 11.5% during the past week and dropped 34.73% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 13.03%. Calithera Biosciences, Inc.
01/28/16 12:21 PMRecent Broker Updates On Calithera Biosciences, Inc. (NASDAQ:CALA) - Risers & Fallers - Recent Broker Updates On Calithera Biosciences, Inc. (NASDAQ:CALA)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Calithera Biosciences, Inc. (NASDAQ:CALA). The latest broker reports which are currently outstanding on Wednesday 27th January state 2 analysts have a rating of “strong ...
01/22/16 06:34 PMCalithera Biosciences, Inc. (NASDAQ:CALA) - Stock Sentiment And ABR Update - Investor Newswire - Calithera Biosciences, Inc. (NASDAQ:CALA) - Stock Sentiment And ABR UpdateInvestor NewswireZacks Research has given an average broker rating of 1 to Calithera Biosciences, Inc. (NASDAQ:CALA)'s shares. Zacks assigns a simplified score in between one and five against the complex analysts' ratings. A score towards 1-2 typically means a ...Calithera Biosciences Announces Abstract Selected for Oral Presentation at the 2016 Keystone SymposiaPharmiWeb.com (press release)all 3 news articles »
01/22/16 03:07 PMCALITHERA BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
01/22/16 11:28 AMCalithera Biosciences Announces Abstract Selected for Oral Presentation at the 2016 Keystone Symposia - PharmiWeb.com (press release) - Calithera Biosciences Announces Abstract Selected for Oral Presentation at the 2016 Keystone SymposiaPharmiWeb.com (press release)22, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that preclinical data for its lead immuno-oncology therapeutic ...and more »
01/22/16 08:23 AMCalithera Biosciences Announces Abstract Selected for Oral Presentation at the 2016 Keystone Symposia - [at noodls] - , (GLOBE NEWSWIRE) -- (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, today announced that preclinical data for its lead immuno-oncology therapeutic ...
12/22/15 07:51 AMWhy Calithera Biosciences (CALA) Stock Might be a Great Pick -
12/09/15 03:40 AMIs Calithera Biosciences Inc (CALA) A Good Stock To Buy? -
12/08/15 12:17 PMCALITHERA BIOSCIENCES, INC. Financials -
12/06/15 09:39 AMCalithera Biosciences Reports Phase I Data for CB-839 in Patients With Hematological Malignancies at the 57th American Society of Hematology Annual Meeting - [at noodls] - First results of CB-839 dosed in combination therapy Promising clinical activity with early signs of biologic activity, tolerability, and durability SOUTH SAN FRANCISCO, Calif., Dec. 06, 2015 (GLOBE NEWSWIRE) ...
11/23/15 07:00 AMBe On Top Of The Latest Developments - Research on EnerNOC, Inventure Foods, KEMET and Calithera Biosciences - [Accesswire] - NEW YORK, NY / ACCESSWIRE / November 23, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: EnerNOC Inc. ...
11/19/15 07:40 AMIs Calithera Biosciences (CALA) Stock a Solid Choice Right Now? -
11/16/15 03:06 PMCalithera Presents Preclinical Study Findings for CB-839 at the 2015 Novel Cancer Therapeutics Summit - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., Nov. 16, 2015-- Calithera Biosciences, Inc., a clinical stage biotechnology company focused on the development of novel cancer therapeutics, will announce new preclinical data ...
11/10/15 04:12 PMEdited Transcript of CALA earnings conference call or presentation 9-Nov-15 9:15pm GMT -
11/09/15 04:45 PMCalithera reports 3Q loss -
11/09/15 03:21 PMCALITHERA BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a -
11/09/15 03:16 PMCalithera Biosciences Reports Third Quarter 2015 Financial Results and Recent Highlights - [at noodls] - Calithera Biosciences Reports Third Quarter 2015 Financial Results and Recent Highlights
About Calithera Biosciences

Calithera Biosciences logoCalithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. Its lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, which is an enzyme that depletes the amino acid arginine, a key metabolic nutrient for T-cells. Its lead preclinical program in tumor immunology is directed at developing inhibitors of the enzyme arginase and may provide a therapeutic agent for the target. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. Hexokinase is an enzyme in the pathway that allows cancer cells to convert glucose to energy to fuel cancer cell growth.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CALA
  • CUSIP:
Key Metrics:
  • Previous Close: $4.21
  • 50 Day Moving Average: $4.72
  • 200 Day Moving Average: $5.61
  • P/E Ratio: N/A
  • P/E Growth: -0.03
  • Market Cap: $75.06M
  • Current Quarter EPS Consensus Estimate: $-2.15 EPS
Additional Links:
Calithera Biosciences (NASDAQ:CALA) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha